DEFA14A ·Filed May 8, 2026

SIGA

SIGA TECHNOLOGIES INC
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001140361-26-020020
Proxy solicitation materials
Actionable Insight • Neutral

Monitor the vote outcome at the June 9, 2026 annual meeting. Passage would enable continued equity grants, while failure could lead to increased cash compensation. The corrective nature of this filing is unlikely to move the stock.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
SIGA ▼ -30.77% at T+60d
NEUTRAL call ✗ call lost -30.77% · α vs SPY -35.16% · entry $4.55 → $3.15
Entry anchored
May 8, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α +0.14%
$4.55
settled 5mo ago
T+5d
-6.15%
call -6.15% · α -6.07%
$4.27
settled 5mo ago
T+20d
-3.52%
call -3.52% · α -3.21%
$4.39
settled 4mo ago
T+60d
-30.77%
call -30.77% · α -35.16%
$3.15
settled 8w ago

Price Chart

Loading chart...

Executive Summary

SIGA Technologies filed a DEFA14A supplement to its 2026 proxy statement, correcting errors in Proposal 4 regarding the amendment to the 2010 Stock Incentive Plan. The corrections remove a non-employee director compensation cap and clarify that the 1,000,000-share annual limit applies only to employees. The board continues to recommend approval of the amendment, which would increase the share pool by 6.5 million shares.

Key Facts

  • The supplement corrects errors in the original proxy statement regarding Proposal 4 (stock plan amendment).
  • Removes erroneous non-employee director compensation cap and clarifies 1,000,000-share limit applies only to employees.
  • Full text of the 2010 Stock Incentive Plan is included as Annex B.
  • Annual meeting scheduled for June 9, 2026; board recommends voting FOR the amendment.
  • The amendment would increase authorized shares from 8.5 million to 15 million (6.5 million new shares).

Financial Impact

No immediate financial impact; the filing is a corrective supplement. If approved, the additional 6.5 million shares represent potential dilution of approximately 12.07% on a fully diluted basis (per company disclosure).

dilution

Risk Factors

  • Failure to approve the amendment could force the company to use cash compensation, potentially impacting cash flow.
  • Approval allows significant equity dilution (12.07% fully diluted overhang), though management claims low burn rate (1.16% 3-year average).

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001140361-26-020020
Document: 0001140361-26-020020-index-headers.html0001140361-26-020020
Document: 0001140361-26-020020-index.html0001140361-26-020020
Document: 0001140361-26-020020.txt0001140361-26-020020
3 reports for SIGA
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for SIGA — sortable, filterable
TypeNow
May 8, 2026
20w ago
DEFA14A
NEUTRAL ★ 2/10
$4.55 $3.15▼ −30.77%▼ −35.16%$3.37 (−25.93%)
May 7, 2026
21w ago
Press Release
BEARISH ★ 6/10
$4.80 $3.24▲ +32.50%▲ +37.34%$3.37 (+29.79%)
Mar 26, 2026
27w ago
Press Release
NEUTRAL ★ 4/10
$4.69 $4.34▼ −7.43%▼ −23.50%$3.37 (−28.12%)
Showing 3 of 3

US Market Status

Market Open — Closes in 43m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access